8-K: Processa Pharmaceuticals Grants Exclusive Option for Gastroparesis Drug, PCS12852, to Intact Therapeutics in Potential $452.5 Million Deal

Processa Pharmaceuticals, Inc. has entered into a binding term sheet granting Intact Therapeutics an exclusive option to license its Phase 2B-ready drug candidate, PCS12852, for diabetic gastroparesis, with potential payments totaling up to $452.5 million.

Summary

• Processa Pharmaceuticals, Inc. (PCSA) signed a Binding Term Sheet with Intact Therapeutics, granting Intact an exclusive option to license PCS12852.
• PCS12852 is a highly specific and potent 5HT4 agonist, ready for Phase 2B clinical trials, targeting diabetic gastroparesis.
• Upon execution of the Term Sheet, Processa received a non-refundable standstill payment of $20,000.
• If a definitive license agreement is executed, Processa will receive a 3.5% equity interest in Intact and a $2.5 million payment ($1.0 million within 30 days, $1.5 million within 12 months).
• The license agreement is expected to include development and regulatory milestone payments up to $20 million, and commercial milestone payments exceeding $432.5 million based on net product sales.
• Processa will also receive a 12% royalty on worldwide net sales of licensed products, excluding South Korea.
• Processa is required to share a percentage of cash payments received from sublicenses with its original licensor, Yuhan Corporation: 60% for sublicenses prior to Phase 2B, 50% after Phase 2B, and 40% after Phase 3.
• The deal is contingent on additional due diligence by Intact, negotiation and execution of a definitive license agreement, and an amendment to Processa's existing license agreement with Yuhan Corporation.
• The parties have 120 days to finalize due diligence and enter the license agreement, with a possible 120-day extension for an additional $30,000 fee.

Sentiment

Score: 7

Explanation: The announcement is largely positive, indicating a strategic move to monetize a non-core asset with significant potential future payments and an equity stake. However, the conditional nature of the definitive agreement and the requirement to share a substantial portion of payments with a third party introduce some uncertainty, preventing a 'strong positive' sentiment.

Positives

• Unlocks potential significant value from a non-oncology asset (PCS12852), allowing Processa to focus on its core mission of developing next-generation cancer therapies.
• Provides immediate non-refundable payment of $20,000 and potential near-term payments of $2.5 million upon license execution.
• Offers substantial future revenue potential through development, regulatory, and commercial milestones totaling up to $452.5 million, plus double-digit royalties (12%) on worldwide net sales.
• Secures an equity stake of 3.5% in Intact Therapeutics, providing shared upside in the development and commercialization of PCS12852.
• Partners with Intact Therapeutics, a company with an innovative delivery platform and GI-focused strategy, deemed an ideal partner to advance PCS12852.
• PCS12852 has demonstrated a favorable safety and efficacy profile in clinical studies and is considered a potentially best-in-class approach for gastroparesis.

Negatives

• Processa must share a significant portion of cash payments received from the sublicense with its original licensor, Yuhan Corporation (60% prior to Phase 2B, 50% after Phase 2B, 40% after Phase 3).
• The definitive license agreement is subject to several conditions, including additional due diligence by Intact and an amendment to Processa's license agreement with Yuhan Corporation.
• There is no assurance that Processa and Intact will enter into a definitive license agreement or that Yuhan Corporation will agree to amend the existing license agreement.

Risks

• The Company and Intact may not enter into a definitive license agreement, which would prevent Processa from receiving the substantial milestone payments, royalties, and equity interest.
• Yuhan Corporation may not agree to amend the existing license agreement with Processa, which is a condition for the exclusive license to become effective.
• Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements due to various risk factors identified in SEC filings.

Future Outlook

Processa Pharmaceuticals expects to enter into a definitive license agreement with Intact Therapeutics for PCS12852, contingent on further due diligence and an amendment to its existing license agreement with Yuhan Corporation. If successful, this partnership aims to advance PCS12852 towards commercialization as a potential first meaningful treatment for gastroparesis, while Processa focuses on its oncology pipeline.

Management Comments

• George Ng, CEO of Processa: "This agreement is another example of how we can unlock the value of our non-oncology assets while remaining laser-focused on our mission of developing next-generation cancer therapies."
• George Ng, CEO of Processa: "We believe Intact's innovative delivery platform and GI-focused strategy make them an ideal partner to advance PCS12852 toward commercialization."
• Ravi Pamnani, CEO and Co-Founder of Intact Therapeutics: "At Intact, we are building a company around the idea that there remain significant unmet clinical needs in GI – not only to treat disease but also to radically improve patient quality of life."
• Ravi Pamnani, CEO and Co-Founder of Intact Therapeutics: "PCS12852's strong clinical data in improving gastric motility and clean safety profile make it an ideal candidate to add to our GI portfolio. We are thrilled to partner with Processa and advance this asset through our development pipeline."
• Lorin K. Johnson, Ph.D., Board Member and Scientific Advisor to Intact Therapeutics: "The safety profile and high selectivity of PCS12852 make it a promising therapeutic option for patients with a wide range of GI motility disorders."
• Lorin K. Johnson, Ph.D., Board Member and Scientific Advisor to Intact Therapeutics: "The partnership between Intact and Processa will provide strategic alignment and shared upside to create value for both companies."

Industry Context

The announcement highlights the significant unmet clinical need in gastrointestinal (GI) motility disorders, particularly gastroparesis, which is a debilitating condition with limited treatment options. PCS12852, a selective 5-HT4 receptor agonist, aims to address this by restoring normal gastric emptying without the cardiovascular and central nervous system side effects seen with older agents in this class, positioning it as a potentially best-in-class and highly differentiated treatment option in the GI therapeutic area.

Stakeholder Impact

• Shareholders: Potential for significant future revenue streams and an equity stake in Intact Therapeutics, which could enhance shareholder value if the definitive agreement is finalized and PCS12852 is successfully developed.
• Patients: Potential for a new, effective, and safer treatment option for diabetic gastroparesis and other GI motility disorders, addressing a high unmet medical need.
• Employees: No direct impact mentioned, but successful asset monetization could strengthen the company's financial position.
• Yuhan Corporation: Will receive a significant percentage of cash payments from the sublicense, as per the amended license agreement.

Next Steps

• Intact Therapeutics to conduct additional due diligence on PCS12852.
• Processa Pharmaceuticals and Intact Therapeutics to negotiate and execute a definitive license agreement within 120 days (extendable for another 120 days).
• Processa Pharmaceuticals to enter into Amendment No. 1 to its License Agreement with Yuhan Corporation to facilitate the sublicense.
• Intact Therapeutics to advance PCS12852 through its development pipeline, including Phase 2B clinical trials, towards commercialization.

Key Dates

Keywords

Processa Pharmaceuticals, Intact Therapeutics, PCS12852, Gastroparesis, 5HT4 agonist, License agreement, Biopharmaceutical, Clinical-stage, Milestone payments, Royalties, Diabetic gastroparesis, GI motility disorders, SEC filing, 8-K, PCSA